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Psychiatric comorbiditiesIn a cross-sectional study, we evaluated the impact of the chronic use of benzodiazepines (BDZ) prescribed for
seizure control on the anxiety levels of patients with temporal lobe epilepsy. We assessed the anxiety level of
99 patients with temporal lobe epilepsy with (n=15) or without (n=84) BDZ for seizure control, using the
Beck Anxiety Inventory (BAI) or the Hamilton Anxiety Scale (HAMA). Independent risk factors for high anxiety
levels were being a female patient (O.R.=2.93; 95% C.I.=1.05–8.16; p=0.039), having uncontrolled seizures
(O.R.=4.49; 95% C.I.=1.66–12.11; p=0.003) and having a history of a psychiatric disorder (O.R.=4.46; 95%
C.I.=1.63–12.21; p=0.004). However, there were no statistically signiﬁcant differences in anxiety levels be-
tween patients utilizing or not utilizing BDZ prescribed exclusively for seizure control. We concluded that in
our study, patients with chronic use of BDZ prescribed exclusively for seizure control showed similar anxiety
levels than patients whowere not using this class of drug. Additional studies are needed to deﬁne better strat-
egies for the treatment of anxiety disorders in epilepsy.
© 2011 Elsevier Inc. Open access under the Elsevier OA license. 1. Introduction
Epilepsy is a frequent disease, occurring in 0.5 to 1.5% of the
population [1]. The association between epilepsy and psychiatric dis-
orders is well recognized and has been extensively studied. Psychi-
atric comorbidities occur in 20–80% of patients with epilepsy [2,3].
This broad range prevalence might be due to the different popula-
tions studied and to the variability of the diagnostic criteria used. In
a community-based study, Tellez-Zenteno et al. used the Canadian
Community Health Survey—Mental Health and Well-Being (CCHS-
MHWB) to analyze the prevalence of psychiatric comorbidities in
epilepsy [4]. These authors reported that individuals with epilepsy
were more likely than individuals without epilepsy to report lifetime
anxiety disorders or suicidal thoughts [4]. In our patients with
temporal lobe epilepsy (TLE), we observed high levels of psychiatric
comorbidities, and our results are comparable to those reported
for European populations [5,6]. Some data suggest that genetic and
anatomically common neural networks might merge together leading
to the development of psychiatric comorbidities in epilepsy [7–10].
There is much evidence that the presence of psychiatric disorders
in patients with epilepsy has a stronger impact on quality of life thanHospital de Clínicas de Porto
03, Brazil.
anchin).
OA license. other clinical variables, including frequency or severity of seizures
[11,12]. For example, depression but not seizure control might predict
quality of life in epilepsy [12]. Although anxiety comorbidities are as
frequent as mood disorders in epilepsy, risk factors for their develop-
ment or their impact on patients are much less studied, and their
treatment still needs to be better deﬁned [13].
Benzodiazepines (BDZ) are frequently used as an add-on therapy
for seizure control in epilepsy [14–16]. These drugs can also be used
for the treatment of anxiety disorders [17–19]. It might be intuitive
to some neurologists to consider that BDZ could be used to control
seizures and reduce anxiety levels associated with epilepsy in some
patients. Thus, we designed this study to evaluate the impact of BDZ
chronically used as an add-on therapy for seizure control on anxiety
levels in patients with epilepsy. Our study might be relevant for the
treatment of anxiety disorders in patients with epilepsy.
2. Methods
2.1. Subjects
This was a cross-sectional study conducted on 99 consecutive
patients (62 women and 37 men) with TLE. Patients were selected
from the Epilepsy Program of Hospital de Clínicas de Porto Alegre, a
tertiary hospital located in the Southern Region of Brazil. Porto Alegre
is the capital of Rio Grande do Sul State. The city has a population
of 1,416,735 distributed in an area of 496.8 km2. A large part of the
Table 1
Clinical characteristics of patients according to BDZ use.
All patients
n (%)
With BDZ
n (%)
Without BDZ
n (%)
p
Mean age of patients
(mean, S.D.)
99 (100) 38.4 (11.3) 46.9 (13.1) 0.02a
Mean age at epilepsy
onset (mean, S.D.)
99 (100) 9.8 (5.5) 22.9 (14.8) 0.001a
Mean time of epilepsy
(mean, S.D.)
99 (100) 28.0 (14.4) 23.6 (14.8) 0.29
Female 62 (62.6) 8 (53.3%) 54 (64.3%) 0.56
More than 8 years of
education
53 (53.5) 10 (66.7%) 43 (51.2%) 0.40
Married 49 (49.5) 04 (26.7%) 45 (53.6%) 0.09
History of alcohol or
drug abuse
03 (96.0) 03 (20.0%) 0 (0.0%) 1.00
History of tobacco abuse 13 (13.3) 02 (13.3%) 11 (13.9%) 0.70
Positive family history
of epilepsy
40 (40.4) 05 (33.3%) 35 (41.7%) 0.77
Positive family history of
psychiatric disorders
57 (57.6) 09 (60.0%) 48 (57.1%) 1.00
Poor seizure control 54 (54.5) 12 (80.0%) 42 (50.0%) 0.047a
Lateralized EEG focus 51(51.5) 06 (40.0%) 45 (53.6%) 0.62
Presence of anxiety
disorders (SCID)
30 (30.3) 04 (26.7%) 26 (30.9%) 1.00
Presence of mood
disorders (SCID)
42 (42.4) 06 (40.0%) 36 (42.8%) 1.00
Monotherapy 62 (62.6) 07 (46.7%) 55 (65.5%) 0.25
S.D.: standard deviation; BDZ: benzodiazepine; EEG: electroencephalography.
a Signiﬁcant.
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Germans, Italians, and Portuguese [20].
The inclusion criterion for the study was the presence of electrocli-
nical and neuroimaging features of TLE, according to the ILAE
classiﬁcation for epileptic seizures and syndromes. Patients less than
18 years of age, those with generalized epilepsies, extratemporal
epilepsies, mental retardation (IQ scores below 70), brain tumor,
systemic disease, or penetrating head trauma, and those patients in
treatment for depression or anxiety were excluded. Only patients
using BDZ strictly as an adjuvant drug for seizure control (e.g.
clobazam or clonazepam) were included in the study. Patients using
BDZ for a reason other than seizure control were also excluded from
the study. After giving written informed consent, all patients were
submitted to the Beck Anxiety Inventory (BAI) and Hamilton Anxiety
Scale. The BAI scale classiﬁes patients into four levels: minimum,
mild, moderate, and severe anxiety levels. In order to facilitate data
analysis and presentation, the results of the BAI scale were divided
into twomajor groups, i.e., patientswith low anxiety levels (minimum
or mild anxiety levels) and patients with high anxiety levels (moder-
ate or severe anxiety levels). The two different scales were used inTable 2
Anxiety levels according to patient characteristics.
Patients Beck Anxiety Inventory (n, %)
n (%) Low anxiety High anxiety p
Women 62 (62.2%) 29 (29.3%) 33 (33.3%) 0.08
Less than 8 years of education 46 (46.4%) 23 (23.2%) 23 (23.2%) 0.54
No drug/alcohol abuse 96 (96.9%) 52 (52.5%) 44 (44.4%) 0.59
No tobacco abuse 69 (69.6%) 36 (36.4%) 33 (33.3%) 0.76
Married 49 (49.4%) 30 (30.3%) 19 (19.2%) 0.16
No family history of epilepsy 59 (59.5%) 31 (31.3%) 28 (28.3%) 0.80
No family psychiatric disorders 42 (42.4%) 24 (24.2%) 18 (18.2%) 0.54
Seizures controlled 45 (45.4%) 33 (33.3%) 12 (12.1%) 0.001a
Lateralized EEG focus 51 (51.5%) 25 (12.1%) 26 (12.1%) 0.35
No anxiety disorders 69 (69.6%) 43 (43.4%) 26 (26.3%) 0.009a
No mood disorders 57 (57.5%) 39 (39.4%) 18 (18.2%) 0.001a
Monotherapy 62 (62.6%) 35 (35.3%) 27 (27.3%) 0.53
a Signiﬁcant.order to obtain more accurate results. All patients were previously
evaluated with the Structured Clinical Interview for DSM-IV (SCID),
for the detection of one or more lifetime diagnoses of the Axis I Diag-
nostic and Statistical Manual, fourth edition (DSM-IV). Clinical charts
were reviewed for EEG and neuroimaging ﬁndings. Control of seizures
was assessed with an event calendar ﬁlled out by the patient and re-
vised during visits. Seizures occurring more than once a year were
considered to be uncontrolled. Data regarding current antiepileptic
treatments, including BDZ used strictly as adjuvant drugs for seizure
control, were recorded in a database for later analysis. The study was
approved by the Ethics Committee of our institution and conformed
to the ethical standards as deﬁned by the Declaration of Helsinki. All
persons included in the study gave written informed consent prior
to their inclusion in the study.
2.2. Statistical analysis
The clinical and electroencephalographic variables and anxiety
levels were compared between TLE patients taking or not taking BDZ
for seizure control. Categorical variables were compared using Fisher's
exact test. Numerical variables were compared using the independent
Student t-test with the Levene test for equality of analysis of variance.
All statistical analyses were carried out using the SPSS 16.0 statistical
package for Windows (SPSS Inc., Chicago, IL, USA). Results are
expressed as mean (standard deviation) or percentages (odds ratio;
95% conﬁdence interval). We used a logistic regression model in order
to further examine the independent effect of each risk factor in
contributing to high anxiety levels in patients with epilepsy and to
control for confounding factors regarding the use or not of BDZ. The
level of signiﬁcance was set at pb0.05.
3. Results
Variables according to the use of BDZ are listed in Table 1. The
mean age of the patients was 45.63 (±13.18) years, mean age of
epilepsy onset was 20.98 (±14.58) years, and mean time of epilepsy
was 24.25 (±14.76) years. In our sample, patients taking BDZ had a
lower mean age of epilepsy onset. Fifteen patients (15.15%) were
using BDZ strictly prescribed as adjuvant drugs for seizure control.
Of these, 13 (86%) were using clobazam (a mean dose of 24 mg/day,
ranging from 10 to 40 mg/day) and 2 (14%) were using clonazepam
(a mean dose of 2 mg/day, ranging from 2 to 2 mg/day). As expected,
the use of BDZ was more common among patients with refractory
epilepsy (O.R.=5.6; 95% CI=1.97–11.06; p=0.047) since BDZ
were used in an attempt to control seizures in these patients. No
other difference was observed between the two groups of patients.
Table 2 shows the variables according to anxiety levels. In order to
facilitate evaluation, anxiety levels are expressed as BAI low anxietyHamilton Anxiety Scale (mean, S.D.)
Psychic Subscale p Somatic Subscale p Total score p
12.5 (6.8) 0.02a 8.9 (5.6) 0.23 21.4 (11.8) 0.05
11.4 (7.2) 0.84 8.5 (5.5) 0.89 19.9 (11.9) 0.84
11.4 (6.7) 0.44 8.5 (5.3) 0.62 19.8 (11.3) 0.46
11.6 (6.7) 0.42 8.2 (5.2) 0.83 19.8 (11.3) 0.57
10.1 (6.3) 0.09 7.5 (4.5) 0.08 17.6 (9.8) 0.07
11.9 (6.7) 0.23 8.7 (5.4) 0.56 20.6 (11.3) 0.30
9.6 (6.6) 0.03a 7.6 (5.1) 0.16 17.1 (11.3) 0.05
10.3 (6.9) 0.17 7.7 (5.4) 0.22 18.0 (11.7) 0.17
12.0 (6.6) 0.23 8.3 (5.1) 0.74 20.3 (11.1) 0.60
9.6 (6.6) b0.001a 7.2 (4.8) b0.001a 16.8 (10.6) b0.001a
8.1 (5.8) b0.001a 6.4 (4.6) b0.001a 14.4 (9.8) b0.001a
11.2 (6.7) 0.85 8.1 (5.2) 0.44 19.2 (11.5) 0.61
Table 3
Anxiety levels of patients using or not using benzodiazepines.
Total sample (n=99) With BDZ (n=15) Without BDZ (n=84) p
Hamilton Scale for anxiety
Total score (mean, S.D.) 20.7 (12.4) 19.6 (11.2) 0.70
Psychic Subscale (mean, S.D.) 11.9 (6.9) 11.2 (6.7) 0.69
Somatic Subscale (mean, S.D.) 8.8 (6.2) 8.4 (5.1) 0.77
Beck Anxiety Inventory
High anxiety 09 (60%) 37 (44%)
Low anxiety 06 (40%) 47 (56%) 0.28
S.D. = standard deviation; BAI = Beck Anxiety Inventory; BDZ = benzodiazepine.
375A.D. Pizzol et al. / Epilepsy & Behavior 23 (2012) 373–376(minimal or mild anxiety levels) or BAI high anxiety (moderate or
severe anxiety levels). Hamilton results (Total Hamilton Score,
Hamilton Psychic Subscale, and Hamilton Somatic Subscale) are
reported as mean (±S.D.). Overall, we observed that being a woman
or having anxiety or mood disorders as detected previously by SCID
was associated with higher anxiety in BAI or Hamilton Total scores.
BAI detected high levels of anxiety also in patients with uncontrolled
seizures, andHamilton scores showedhigher anxiety levels in patients
with a family history of psychiatric disorders. No other differences
were observed (Table 2). Moreover, there were no differences when
mean age of patients or mean age of seizure onset was compared
between groups of BAI low anxiety and BAI high anxiety levels. Also,
there was no correlation between mean age of patients and mean
age of seizure onset regarding the results of the Hamilton Anxiety
Scale (data not shown).
Table 3 shows the Hamilton Scale and the BAI results for patients
using BDZ as an adjuvant drug for seizure control. An analysis of
subgroups of patients with or without psychiatric disorders as
detected by SCID showed similar ﬁndings (data not shown). Table 4
shows independent predictors of high anxiety in our patients. We
forced into the model the use of BDZ in order to control its effects
but again, failed to observe a positive effect of the chronic use of
BDZ in decreasing anxiety levels in patients with TLE. Thus, in our
study, patients with chronic use of BDZ prescribed exclusively for
seizure control showed similar anxiety levels than those patients
with epilepsy who were not using BDZ.4. Discussion
Our results showed equivalent levels of anxiety among patients
with epilepsy who were and who were not using benzodiazepines
for seizure control. This was observed in the group of patients as
a whole and also in those patients with or without psychiatric
comorbidities previously detected by SCID. Thus, in spite of some
biological plausibility and some expectations, our ﬁndings suggest
that the chronic use of BDZ prescribed as an add-on therapy forTable 4
Logistic regression for high anxiety in Beck Anxiety Inventory.
Variable Crude odds ratio Adjusted odds ratio
Odds
ratio
95% CI p Odds
ratio
95% CI p
Women 2.13 (0.91–5.00) 0.08 2.93 (1.05–8.16) 0.039a
Married 0.54 (0.24–1.20) 0.16 0.49 (0.19–1.30) 0.14
Uncontrolled
seizures
4.67 (1.97–11.06) b0.001a 4.49 (1.66–12.11) 0.003a
Positive SCID 4.35 (1.79–10.54) 0.001a 4.46 (1.63–12.21) 0.004a
Use of BDZ 1.90 (0.62–5.83) 0.27 1.67 (0.43–6.67) 0.45
BDZ: benzodiazepine; CI: conﬁdence interval; SCID: Structured Clinical Interview for
DSM-IV.
a Signiﬁcant.seizure control might not be clinically effective for the treatment of
anxiety symptoms in epilepsy.
The studies of anxiety disorders in epilepsy have been neglected,
and treatments for this comorbidity in patients with epilepsy remain
poorly explored [8,13]. Moreover, because there is a well-known asso-
ciation betweenmood and anxiety disorders, most studies and clinical
observations might not be sufﬁciently discriminatory to evaluate the
real impact of these treatments on anxiety symptoms in epilepsy.
When speciﬁc treatments for anxiety comorbidities in epilepsy are
proposed, they are mostly based on psychiatric experience [8,9]. In
psychiatric patients, pharmacological treatments for anxiety disorders
are based mainly on selective serotonin reuptake inhibitors (SSRIs),
tricyclic antidepressants (TCAs) or BDZ. Besides being ﬁrst line in anx-
iety disorder therapy, the use of SSRIs and TCAs is also effective for
mood disorders, a comorbidity that is often associated with anxiety
disorders in epilepsy. BDZ are not considered ﬁrst line for the treat-
ment of anxiety disorders due to tolerance or addiction. On the other
hand, BDZ (e.g. clobazam and clonazepam)might be used as a chronic
add-on therapy for seizure control [14,18]. Thus, at least for some pa-
tients, BDZ would be perhaps natural candidates for the treatment of
anxiety symptoms as well. However, in spite of some clinical and bio-
logical plausibility, our results do not support this idea. In fact, we ob-
served that the anxiety levels were similar when patients with
epilepsy chronically using BDZ as an add-on therapy for seizure con-
trol were compared to the respective control group.
In our study, independent variables associated with anxiety disor-
ders in TLE were being a female or having anxiety or mood disorders
as detectedpreviously by SCID. These patients had higher anxiety scores
when tested with BAI as well as with Hamilton. BAI also detected high
levels of anxiety in patients with uncontrolled seizures, and Hamilton
showed higher anxiety levels in patientswith a family history of psychi-
atric disorders. The neurobiology of anxiety comorbidities in epilepsy
remains not fully understood. Some authors relate anxiety as a reaction
to real or imaginary threats, a view in line with learning and cognitive–
behavioral theories, suggesting that anxiety is a conditioned response to
stressful stimuli [8,21,22]. In this regard, it was interesting that in our
study, we observed high levels of anxiety in patients with uncontrolled
seizures. It is plausible that anxiety in epilepsy is provoked or at least
potentiated by fear of seizures, a view in line with the learning and cog-
nitive–behavioral theories. Nevertheless, this ﬁnding is also in linewith
other neurobiological hypotheses [8]. It is possible that insufﬁciency of
neural substrates in regulating overexcitability and other mechanisms
that render patients prone to refractory seizures also predispose pa-
tients to anxiety disorders. We also observed that female sex or having
mood disorders was independently associated with higher anxiety
levels in patients with epilepsy. Other authors have reported similar
ﬁndings [23,24]. Finally, it was interesting to observe that patients
with a family history of psychiatric disorders (e.g. mood or anxiety dis-
orders) showed higher anxiety levels on theHamilton Rating Scale. This
observation might suggest that genetic and molecular mechanisms
might be involved in anxiety comorbidity in patients with epilepsy.
Anxiety disorders in epilepsy are probably of multifactorial etiology,
and it is possible that several factors merge together leading to the neu-
ropsychiatric symptoms. Some of these factors were pointed out by our
study.
We recognize that our study has limitations. It is a cross-sectional
study and not a prospective study speciﬁcally designed for the eval-
uation of the impact and variability of effect of BDZ over time. More-
over, our study was not designed to evaluate the short-term effect of
BDZ on anxiety symptoms. Although all patients underwent formal
psychiatric evaluation with SCIDs, we did not analyze the impact of
BDZ on speciﬁc sub-types of anxiety comorbidities in our patients.
Also, in order to detect small effects of BDZ, the number of patients
included in our study should have been higher. Moreover, since we
did not obtain a pre-benzodiazepine anxiety baseline in our patients,
we did not study the real effect of the BDZ prescription on the anxiety
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receiving BDZ exclusively prescribed for seizure control, we cannot
completely exclude that more anxious patients were prescribed
BDZ more often. Finally, the doses of BDZ were not very high, but
were the maximum tolerated dosages for chronic use in these patients.
However, on the other hand, our study has some merits that deserve
recognition as well. We evaluated patients chronically taking BDZ
with maximum tolerated doses. We used two different scales to evalu-
ate anxiety symptoms, and we controlled the results for confounding
variables, with congruent results for both scales. Studies evaluating
the impact of the long-term use of BDZ on anxiety symptoms in pilepsy
are clearly needed, and as far as we know, this is one of the ﬁrst studies
addressing the chronic effects of BDZ on the anxiety levels of patients
with epilepsy. Thus, we believe that our resultsmight help develop bet-
ter treatment strategies for anxiety comorbidities in epilepsy in the near
future.
5. Conclusion
In conclusion, we did not observe a difference in anxiety levels
between patients using or not using BDZ chronically for seizure
control. It is plausible that chronic use of BDZ could induce tolerance
to the anxiolytic effect of these drugs in patients with epilepsy. In
our view, additional studies are needed to deﬁne speciﬁc strategies
for the treatment of anxiety disorders in epilepsy. Nevertheless, we
hope that our study might help neurologists and psychiatrists in the
decision-making process regarding the treatment of anxiety disorders
in epilepsy in the near future.
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